Financial & Investment Management Group Ltd. Purchases 15,633 Shares of Agios Pharmaceuticals Inc (AGIO)

Share on StockTwits

Financial & Investment Management Group Ltd. raised its position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 53.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,891 shares of the biopharmaceutical company’s stock after acquiring an additional 15,633 shares during the quarter. Financial & Investment Management Group Ltd. owned approximately 0.08% of Agios Pharmaceuticals worth $3,462,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of AGIO. Wells Fargo & Company MN increased its position in Agios Pharmaceuticals by 2.4% in the first quarter. Wells Fargo & Company MN now owns 72,776 shares of the biopharmaceutical company’s stock worth $5,952,000 after buying an additional 1,711 shares in the last quarter. Northern Trust Corp increased its position in Agios Pharmaceuticals by 15.3% in the first quarter. Northern Trust Corp now owns 269,108 shares of the biopharmaceutical company’s stock worth $22,008,000 after buying an additional 35,708 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Agios Pharmaceuticals in the first quarter worth about $6,268,000. Principal Financial Group Inc. increased its position in Agios Pharmaceuticals by 11.5% in the first quarter. Principal Financial Group Inc. now owns 14,895 shares of the biopharmaceutical company’s stock worth $1,218,000 after buying an additional 1,533 shares in the last quarter. Finally, UBS Group AG increased its position in Agios Pharmaceuticals by 200.6% in the first quarter. UBS Group AG now owns 87,642 shares of the biopharmaceutical company’s stock worth $7,167,000 after buying an additional 58,486 shares in the last quarter. 93.63% of the stock is currently owned by institutional investors.

In related news, insider Scott Biller sold 3,000 shares of the stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $83.07, for a total transaction of $249,210.00. Following the completion of the transaction, the insider now directly owns 60,196 shares of the company’s stock, valued at $5,000,481.72. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Steven L. Hoerter sold 2,050 shares of the stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $84.58, for a total value of $173,389.00. Following the transaction, the insider now directly owns 2,050 shares of the company’s stock, valued at $173,389. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,355 shares of company stock valued at $2,148,062. 3.02% of the stock is owned by corporate insiders.

A number of brokerages have commented on AGIO. BidaskClub cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, October 6th. Canaccord Genuity restated a “buy” rating and issued a $90.00 price target on shares of Agios Pharmaceuticals in a research report on Wednesday, September 5th. Piper Jaffray Companies set a $125.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 2nd. SunTrust Banks restated a “buy” rating and issued a $123.00 price target on shares of Agios Pharmaceuticals in a research report on Monday, July 23rd. Finally, Leerink Swann started coverage on Agios Pharmaceuticals in a research report on Monday, September 24th. They set a “market perform” rating and a $80.00 target price for the company. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $96.27.

Shares of NASDAQ:AGIO traded down $5.14 during trading on Thursday, hitting $66.42. 18,148 shares of the company’s stock were exchanged, compared to its average volume of 442,512. Agios Pharmaceuticals Inc has a 52-week low of $51.62 and a 52-week high of $99.82. The stock has a market capitalization of $4.47 billion, a P/E ratio of -10.09 and a beta of 1.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.62) by $0.43. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The firm had revenue of $40.40 million during the quarter, compared to analysts’ expectations of $12.47 million. During the same quarter last year, the business posted ($1.78) earnings per share. The firm’s revenue was up 257.5% on a year-over-year basis. Research analysts predict that Agios Pharmaceuticals Inc will post -6.11 EPS for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

See Also: Conference Calls and Individual Investors

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply